Assessing Financial Difficulty in Patients with Blood Cancers
Colección de datos
Recopilados desde hoy en adelante - ProspectivoTrastornos de las Proteínas Sanguíneas+18
+ Enfermedades Cardiovasculares
+ Enfermedades hemáticas y linfáticas
Solo Casos
Examinando las características de las personas con una enfermedad para identificar factores genéticos o ambientales que contribuyen a la condición.Resumen
Fecha de inicio: 14 de mayo de 2019
Fecha en la que se inscribió al primer participante.The primary and secondary objectives of the study: PRIMARY OBJECTIVES: I. To estimate the proportion of patients with multiple myeloma (MM) or chronic lymphocytic leukemia (CLL) who report experiencing financial difficulty in the past 12 months. SECONDARY OBJECTIVES: I. To describe the association of patient report of financial difficulty with insurance status. II. To describe the association of patient report of financial difficulty with receiving treatment at sites of care that report offering patients financial guidance through navigators or social workers, and controlling for patient socioeconomic status. III. To describe the types of psychosocial, transportation and financial navigation interventions sites are developing. IV. To identify distinct patterns of financial burden among patients undergoing treatment for MM or CLL. V. To examine the relationship between distinct patterns of financial burden with patient report of financial difficulty, patient socio-demographics, and patient disease characteristics. VI. To estimate the proportion of patients with MM or CLL undergoing treatment who report receiving financial support in the past 12 months. VII. To describe the association of patient report of receiving financial support with receiving treatment at sites of care offering patients financial guidance through navigators or social workers, and with socioeconomic status. VIII. To describe the magnitude of patient concerns regarding treatment and costs of care. IX. To describe the association of patient concerns regarding treatment and costs of care with patient socio-demographics, disease and site of care characteristics. X. To describe the association of financial difficulty with patient self-reported health and well-being. Trial Design: OUTLINE: Participants undergo medical chart abstraction within 1 week and complete telephone interview over 30-45 minutes within 8 weeks after registration.
Protocolo
Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.Se reclutarán 521 pacientes
Número total de participantes que el ensayo clínico espera reclutar.Solo Casos
Elegibilidad
Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.Cualquier sexo
Sexo biológico de los participantes elegibles para inscribirse.A partir de 18 años
Rango de edades de los participantes que pueden unirse al estudio.Voluntarios sanos no permitidos
Indica si personas sanas, sin la condición que se estudia, pueden participar.Condiciones
Patología
Criterios
Inclusion Criteria: PATIENT ELIGIBILITY CRITERIA * Patients must have current diagnosis of chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) * Patients' medical records must be available to the registering institution * Eligible patients must have been prescribed drug-based anticancer therapy, whether administered orally or by infusion, within the prior 12 months. Specifically, eligible patients are those who: * Are presently being treated with infused or orally-administered anticancer therapy, OR * Completed infused or orally-administered anti-cancer therapy in the past 12 months, OR * Were prescribed infused or orally-administered anticancer therapy within the prior 12 months yet chose to forego treatment * Not currently enrolled in a clinical trial in which drug is supplied by the study * Patients with psychiatric illness or other mental impairment that would preclude their ability to give informed consent or to respond to the telephone survey are not eligible * Patients must be able to read and comprehend English or Spanish SITE ELIGIBILITY CRITERIA * Intent to complete the A231602CD Site of Care Survey * Access to patient medical records: Registering institution must have access to patient medical records, either on site or via request from other institutions, if recruiting patients at a site (as medical abstraction is required for collecting study data) * Sites seeking to enroll Spanish- speaking patients must have Spanish speaking staff on site to be able to conduct the informed consent discussion in Spanish
Plan de Estudio
Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.Objetivos del Estudio
Objetivos Primarios
Objetivos Secundarios
Centros del Estudio
Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.Este estudio tiene 116 ubicaciones
Delbert Day Cancer Institute at PCRMC
Rolla, United StatesAbrir Delbert Day Cancer Institute at PCRMC en Google MapsAlaska Oncology and Hematology LLC
Anchorage, United StatesAnchorage Oncology Centre
Anchorage, United StatesKatmai Oncology Group
Anchorage, United States